RELATED PARTY TRANSACTIONS	6 Months Ended
Jun. 30, 2020
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 9—RELATED PARTY TRANSACTIONS MSK is a shareholder of the Company. Under the MSK License Agreement, SADA License Agreement, the CD33 License Agreement, CTA, CFAs, SRA and MDSA, we have expensed costs in the total amount of $5,527,000 and $2,200,000 in the three months ended June 30, 2020 and 2019, respectively, for milestones, minimum royalties, and research and development costs. We expensed costs in the total amounts of $6,576,000 and $3,923,000 in the six months ended June 30, 2020 and 2019, respectively, under these agreements with MSK. Please refer to Note 6 for additional details on our agreements with MSK. As of June 30, 2020 and December 31, 2019, we had a total of $5,455,000 and $4,171,000, respectively, recorded as accounts payable and accrued liabilities related to amounts due to MSK.

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2020

NOTE 9—RELATED PARTY TRANSACTIONS

MSK is a shareholder of the Company. Under the MSK License Agreement, SADA License Agreement, the CD33 License Agreement, CTA, CFAs, SRA and MDSA, we have expensed costs in the total amount of $5,527,000 and $2,200,000 in the three months ended June 30, 2020 and 2019, respectively, for milestones, minimum royalties, and research and development costs. We expensed costs in the total amounts of $6,576,000 and $3,923,000 in the six months ended June 30, 2020 and 2019, respectively, under these agreements with MSK. Please refer to Note 6 for additional details on our agreements with MSK. As of June 30, 2020 and December 31, 2019, we had a total of $5,455,000 and $4,171,000, respectively, recorded as accounts payable and accrued liabilities related to amounts due to MSK.